WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation
In Sept. 2024, WINT reported positive Phase 2b study results of istaroxime in early CS patients. To position istaroxime for Phase 3 readiness,...
263 Views
WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands
Zacks Small-Cap Research Note for Windtree Therapeutics (WINT)
208 Views
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones
Zacks Small-Cap Research Note for Windtree Therapeutics (WINT)
321 Views
No more insights